Papadopoulos A, Pantazis N, Panagopoulos P, Kourkounti S, Xylomenos G, Chini M, Petrikkos G, Sambatakou H, Ioannidou P, Kordosis T, et al. Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. Journal of Chemotherapy. 2012;24:38–47.

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M-L, Babiker A, Porter K, others. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antiviral therapy. 2012;17:1039.

, others. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS (London, England). 2012;26:1691.

Collaborationa HIV-CAUSAL. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clinical infectious diseases. 2012;54:1364–1372.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, et al. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PloS one. 2012;7:e32369.

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Archives of internal medicine. 2012;172:1252–1255.

Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix M-L, Bucher HC, Kucherer C, Zangerle R, Kran A-MB, Porter K, et al. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical infectious diseases. 2012;56:888–897.